Literature DB >> 1002693

Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point.

M S Hershfield, J E Seegmiller.   

Abstract

Purine nucleotide synthesis de novo has been studied in a permanent tissue culture line of human splenic lymphoblasts with particular attention to coordination of control of the proximal (rate-determining) steps with the distal branch point of the pathway. An assay was used which permits simultaneous determination of the overall rate of labeling of all intracellular purines with sodium [14C]formate, as well as the distribution of isotope into all intracellular guanine- and adenine-containing compounds. The guanine to adenine labeling ratio was used as an index of IMP branch point regulation. It was found that exogenous adenine and guanine produce feedback-controlling effects not only on the first step in the de novo pathway, but also on the IMP branch point. Concentrations of adenine which produce less than 40% inhibition of the overall rate of de novo purine synthesis do so by selectively inhibiting adenine nucleotide synthesis de novo by 50 to 70% while stimulating guanine nucleotide synthesis de novo by up to 20%. A reciprocal effect is seen with exogenous guanine. The adenosine analog 6-methylmercaptopurine ribonucleoside selectivity inhibits adenine nucleotide synthesis via the de novo pathway but not from exogenous hypoxanthine. Thus, the reactions of purine nucleotide interconversion, in particular adenylosuccinate synthetase, may be regulated differently in cells deriving their purine nucleotides solely from de novo synthesis than when deriving them via "salvage" of preformed hypoxanthine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1002693

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line.

Authors:  R C Willis; D A Carson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

2.  Tight links between adenine and guanine nucleotide pools in mouse pancreatic islets: a study with mycophenolic acid.

Authors:  P Detimary; C Xiao; J C Henquin
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

3.  Validation and steady-state analysis of a power-law model of purine metabolism in man.

Authors:  R Curto; E O Voit; A Sorribas; M Cascante
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

4.  Proceedings of a symposium on crystal-related arthropathies. 22 October and 23 October, 1982, Bristol Polytechnic, Bristol.

Authors: 
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

5.  An enzymatic spectrophotometric assay for inosinic acid.

Authors:  C Salerno; A Giacomello
Journal:  Experientia       Date:  1981-03-15

Review 6.  Human purine metabolism: some recent advances and relationships with immunodeficiency.

Authors:  G Nuki
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

7.  Regulation of purE transcription in a purE::lac fusion strain of Escherichia coli.

Authors:  R A Levine; M W Taylor
Journal:  J Bacteriol       Date:  1982-03       Impact factor: 3.490

8.  Purine biosynthesis de novo in rat skeletal muscle.

Authors:  T G Sheehan; E R Tully
Journal:  Biochem J       Date:  1983-12-15       Impact factor: 3.857

9.  Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation.

Authors:  M S Hershfield; N M Kredich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

10.  Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.

Authors:  A S Bagnara; M S Hershfield
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.